Abstract:In contrast to those of other cardiac diseases, the morbility and morbidity of congestive cardiac insufficiency are not on the decrease, in spite of significant progress in pharmacological treatments and due to the increased life expectancy of the population. Cardiac transplant is the therapy of choice when cardiac failure becomes pharmacologically intractable, but all over the developed world (not to mention the situation in the underdeveloped countries) the number of heart transplants has reached the limit set by the availability of donor organs. Sooner or later xenotransplants could solve this problem, but even if our most optimistic hopes regarding their development and reliability are met, xenotransplants would still carry the risk of anthropozoonotic viral infections. Finally, as suggested in a recent overview, the way to the long-lasting clinical use of mechanical circulatory support is a long and winding road. Other options are related to tissue or cell cardiac bioassistance. Cardiac-bio-assists are biological approaches to the remedy of progressive cardiac failure based on autologous or heterologous tissue or cell transplantation. Some of the work hypotheses are in pre-clinical evaluation (skeletal muscle ventricle), others are under preliminary (cardiomyoplasty, myocardium reduction, implants of myoblasts derived from skeletal muscle satellite cells and implants of embryonic or adult stem cell-derived myocardiocytes, cellular cardiomyoplasty) or advanced clinical testing (dynamic aortomyoplasty and dynamic cardiomyoplasty). Dynamic cardiomyoplasty is a surgical procedure which could support myocardial function when cardiac insufficiency would become pharmacologically intractable in the mid term. In this procedure a nonessential muscle, the latissimus dorsi (LD), is diverted from its normal role, transferred into the chest, wrapped around the heart (LD wrap), conditioned to fatigue and activated during systole to provide cardiac assistance. The mechanisms of its action are discussed and the risk of myodystrophic lesions of the LD wrap which could reduce the work capability of the pericardial muscle prosthesis remains. We are now addressing some of these issues by means of clinical research on the group of Italian patients of demand dynamic cardiomyoplasty, and by means of animal experiments aimed at the development and testing of new surgical, clinical and biotechnological approaches. In particular, we will discuss whether the increase in the muscle mass of the distal part of the transposed LD is desirable and feasible or if it is mandatory.

[Development in Transplantation of the Skeletal Muscle Myoblast].

Reprogramming Autologous Skeletal Myoblasts to Express Cardiomyogenic Function. Challenges and Possible Approaches.

Myoblast Therapy: from Bench to Bedside

Myoblast and its application in skeletal muscle research

New Perspectives in the Treatment of Damaged Myocardium Using Autologous Skeletal Myoblasts

Transplantation to study satellite cell heterogeneity in skeletal muscle

Advances in Skeletal Muscle Engineering in Biomedical Research

Biological Characteristics and Transgenic Study of Rat Cardiac Fibroblasts Culture in Vitro

Myoblast-based Cardiac Repair: Xenomyoblast Versus Allomyoblast Transplantation

Cardiac-bio-assists: Biological Approaches to Support or Repair Cardiac Muscle.

Myoblast Transplantation for Cardiac Repair: from Automyoblast to Allomyoblast Transplantation

Osteogenesis Imperfecta and Bone Marrow Transplant

Biological Characteristics and Prospects Concerning Clinical Application of Skeletal Muscle Satellite Cells

Myoblast Transplantation Improves Cardiac Function after Myocardial Infarction Through Attenuating Inflammatory Responses.

Overexpression of connexin 43 in skeletal myoblasts: Relevance to cell transplantation to the heart

Cellular dynamics of myogenic cell migration: molecular mechanisms and implications for skeletal muscle cell therapies

Optimization of Xenografting Methods for Generating Human Skeletal Muscle in Mice

The role of multifunctional delivery scaffold in the ability of cultured myoblasts to promote muscle regeneration

The application of bone marrow mesenchymal stem cells and biomaterials in skeletal muscle regeneration

Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy

Biomaterial-based delivery for skeletal muscle repair